1. Home
  2. VITL vs URGN Comparison

VITL vs URGN Comparison

Compare VITL & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$20.04

Market Cap

944.3M

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$18.96

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
URGN
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.3M
922.1M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
VITL
URGN
Price
$20.04
$18.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
7
Target Price
$42.56
$29.29
AVG Volume (30 Days)
2.1M
800.4K
Earning Date
01-01-0001
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
N/A
EPS
1.44
N/A
Revenue
$759,444,000.00
$1,128,000.00
Revenue This Year
$26.07
$119.37
Revenue Next Year
$20.95
$64.79
P/E Ratio
$13.90
N/A
Revenue Growth
25.26
N/A
52 Week Low
$19.75
$3.42
52 Week High
$53.13
$30.00

Technical Indicators

Market Signals
Indicator
VITL
URGN
Relative Strength Index (RSI) 23.17 42.05
Support Level N/A $18.65
Resistance Level $31.02 $20.44
Average True Range (ATR) 1.24 1.63
MACD -0.58 -0.17
Stochastic Oscillator 3.04 25.17

Price Performance

Historical Comparison
VITL
URGN

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: